Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Co-DiagnosticsHAM:C970 63 Forward PE Ratio is 0.00 as of Jul. 20, 2026. GuruFocus rates HAM:C970 with a GF Score™ of 63/100 and a GF Value™ of €4.78. The stock has 6 warning signs investors should review. Among 391 Medical Devices & Instruments companies, Co-Diagnostics ranks worse than 255754.22% on this metric.
Co-Diagnostics (HAM:C970) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Co-Diagnostics Forward PE Ratio Related Terms
Co-Diagnostics Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Co-Diagnostics's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Co-Diagnostics Forward PE Ratio Chart
Co-Diagnostics Annual Data
Trend
2020-12
2021-12
Forward PE Ratio
5.96
19.31
Co-Diagnostics Quarterly Data
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
Forward PE Ratio
9.46
4.86
5.96
5.98
9.57
26.18
19.31
15.15
7.29
HAM:C970 vs ALRTF, SINT, HSCS: Forward PE Ratio Comparison
For the Medical Devices subindustry, Co-Diagnostics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Co-Diagnostics Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Co-Diagnostics's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Co-Diagnostics (HAM:C970) has a Forward PE Ratio of 0.00 as of Jul. 20, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Co-Diagnostics and its competitors. According to the industry distribution chart, Co-Diagnostics ranks #999999 out of 391 companies in the Medical Devices & Instruments industry.
Is Co-Diagnostics' Forward PE Ratio too high?
Co-Diagnostics' current Forward PE Ratio is 0.00. Based on the distribution chart, Co-Diagnostics ranks #999999 out of 391 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Co-Diagnostics has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' Forward PE Ratio compare to ALRTF and SINT?
According to the Medical Devices & Instruments industry distribution chart, Co-Diagnostics ranks #999999 out of 391 companies for Forward PE Ratio. This places Co-Diagnostics in the lower half of its industry. The industry median Forward PE Ratio is 19.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.29, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Co-Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Co-Diagnostics's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current Forward PE Ratio of 0.00. The stock's GF Value™ is €4.78, compared to a current price of €5.55 — trading 16.1% above its estimated fair value. The current Forward PE Ratio is 0.00. Co-Diagnostics' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current Forward PE Ratio is 0.00 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Co-Diagnostics (HAM:C970) Overvalued in 2026?
Based on GuruFocus' analysis, Co-Diagnostics stock appears to be overvalued.
The current stock price of €5.55 is trading 16.1% above its estimated GF Value™ of €4.78.
Key valuation signals for HAM:C970:
Forward PE Ratio: 0.00
GF Value™: €4.78 vs. price of €5.55 (16.1% above fair value)
No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
63GF Score
Get the complete analysis for HAM:C970
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:C970 has been successfully added to your 
